Following the successful completion of early-stage studies, Baxalta will have an option to complete late-stage development and worldwide commercialization.

Under an agreement entered into in 2003, Roche had licensed from Maxygen worldwide commercialization rights to the product candidate.

The agreement grants Gilead worldwide commercialization rights to P-680, an epithelial sodium channel inhibitor, for the treatment of pulmonary diseases.